Novavax CEO says Covid-19 shot could be cleared for the U.S. by May

Novavax is currently conducting three efficacy trials for its Covid-19 vaccines. The vaccine is 96 percent effective against the Wuhan Covid strain and 86 percent effective against the U.K. strain. Stanley Erck, Novavax CEO, joins 'Closing Bell' to discuss when it will be available in the U.S.
Mon, Mar 1 20214:37 PM EST